Shomool, the US-based biotech company, introduces the first comprehensive non-invasive test for Autosomal Recessive Disorders; closes a Seed fund round

Delaware, USA – Shomool, a US-based Biotech firm with a presence in KSA, becomes the first to provide comprehensive Non-Invasive Prenatal Testing for Autosomal Recessive Disorders that helps detect diseases like cystic fibrosis, sickle cell anemia, and Tay-Sachs disease among many others in babies during early pregnancy. Shomool has recently closed a seed fund round to help amplify the company’s innovative technology’s reach.

“The team at Shomool is committed to providing the best possible customer experience, and we have been recognized to provide the best patient care. Our commitment to innovation and using cutting-edge technology is aimed at improving the diagnosis and treatment of rare genetic autosomal recessive diseases,” said Prof. Malak Abed AlThagafi, Founder and CSO of Shomool LLC.

The target market for this testing will include hospitals, fertility clinics, diagnostic labs, and pregnant women globally. The company will present its business in the 6th FII, happening in Riyadh from October 25th to 27th, 2022

Backed by extensive research and proprietary AI analysis technology, the test obtains a likelihood ratio to predict whether the baby is more likely to have an autosomal recessive condition.

“We know that our patients are the reason why we are in the business, which is why we will go the extra mile to get them satisfied. Our zeal to provide quality services improves our partnership while strengthening the trust between us, thus, giving us an edge over others,” said Prof. Malak.

Recently, Shomool made it to the five finalists in Dammam Biotech Valley Competition

Media Contact
Company Name: Shomool
Contact Person: Prof. Malak Abed AlThagafi – Founder and CSO
Email: Send Email
Country: United States

Source: Financial Content